A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
The revenues and profits derived from the new subsidiary will be consolidated in the parent company
_256_384.jpeg)
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
The co-investment of CHF 4 million will result in capacity expansion and support the market introduction of the customer's lead compound
Anti-malaria API facility will be operational in 15-18 months
Ibuprofen and Famotidine Tablets is an AB-rated generic therapeutic equivalent version of Horizon Medicines LLC’s Duexis Tablets, 800 mg/26.6 mg
Robust demand for the product across the Middle East, Africa and Latin America
The govt has rolled out three schemes for promoting the manufacture of API
The company proposes to utilise the net proceeds from the fresh issue towards payment of outstanding purchase consideration
The US FDA has closed the observations pertaining to this audit with an Establishment Inspection Report on the 20th of July 2021
Subscribe To Our Newsletter & Stay Updated
